Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1986 1
1987 1
2000 1
2001 1
2003 2
2012 8
2013 57
2014 112
2015 111
2016 101
2017 113
2018 126
2019 117
2020 116
2021 109
2022 100
2023 101
2024 37

Text availability

Article attribute

Article type

Publication date

Search Results

1,046 results

Results by year

Filters applied: . Clear all
Page 1
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G. Baas P, et al. Lancet. 2021 Jan 30;397(10272):375-386. doi: 10.1016/S0140-6736(20)32714-8. Epub 2021 Jan 21. Lancet. 2021. PMID: 33485464 Clinical Trial.
We hypothesised that this regimen would improve overall survival in MPM. METHODS: This open-label, randomised, phase 3 study (CheckMate 743) was run at 103 hospitals across 21 countries. ...The primary endpoint was overall survival among all participants randomly as …
We hypothesised that this regimen would improve overall survival in MPM. METHODS: This open-label, randomised, phase 3 study (CheckMa …
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
Tsao AS, Pass HI, Rimner A, Mansfield AS. Tsao AS, et al. J Clin Oncol. 2022 Feb 20;40(6):681-692. doi: 10.1200/JCO.21.01567. Epub 2022 Jan 5. J Clin Oncol. 2022. PMID: 34985934 Free PMC article. Review.
Although predictive biomarkers for systemic therapy are not currently in use in clinical practice, it is essential to correctly identify the MPM histology to determine an optimal treatment plan. ...
Although predictive biomarkers for systemic therapy are not currently in use in clinical practice, it is essential to correctly ident …
Malignant pleural mesothelioma: recent developments.
Sinn K, Mosleh B, Hoda MA. Sinn K, et al. Curr Opin Oncol. 2021 Jan;33(1):80-86. doi: 10.1097/CCO.0000000000000697. Curr Opin Oncol. 2021. PMID: 33186182 Review.
Several new blood-based biomarkers have been recently reported including peripheral blood DNA methylation, microRNAs, fibulin, and high-mobility group box 1, but have not been established in clinical routine use yet. Regarding treatment, targeted therapies, immunotherapy, …
Several new blood-based biomarkers have been recently reported including peripheral blood DNA methylation, microRNAs, fibulin, and high-mobi …
Immunotherapy approaches for malignant pleural mesothelioma.
Fennell DA, Dulloo S, Harber J. Fennell DA, et al. Nat Rev Clin Oncol. 2022 Sep;19(9):573-584. doi: 10.1038/s41571-022-00649-7. Epub 2022 Jul 1. Nat Rev Clin Oncol. 2022. PMID: 35778611 Review.
In this Review, we comprehensively summarize the key steps in the development of immunotherapies for mesothelioma, focusing on strategies that have led to randomized clinical evaluation and emerging predictors of response. ...
In this Review, we comprehensively summarize the key steps in the development of immunotherapies for mesothelioma, focusing on strategies th …
The Molecular Basis of Malignant Pleural Mesothelioma.
Wadowski B, De Rienzo A, Bueno R. Wadowski B, et al. Thorac Surg Clin. 2020 Nov;30(4):383-393. doi: 10.1016/j.thorsurg.2020.08.005. Epub 2020 Sep 12. Thorac Surg Clin. 2020. PMID: 33012428 Free PMC article. Review.
This article reviews these features and discusses the implications of advances in MPM molecular biology in clinical practice....
This article reviews these features and discusses the implications of advances in MPM molecular biology in clinical practice....
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, Nowak AK, Fujimoto N, Tsao AS, Mansfield AS, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G. Peters S, et al. Ann Oncol. 2022 May;33(5):488-499. doi: 10.1016/j.annonc.2022.01.074. Epub 2022 Feb 3. Ann Oncol. 2022. PMID: 35124183 Free article. Clinical Trial.
PATIENTS AND METHODS: Adults with previously untreated, histologically confirmed, unresectable MPM and Eastern Cooperative Oncology Group performance status of 1 were randomized 1 : 1 to nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks) for up to 2 …
PATIENTS AND METHODS: Adults with previously untreated, histologically confirmed, unresectable MPM and Eastern Cooperative Oncology Group pe …
Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma.
Lim E, Darlison L, Edwards J, Elliott D, Fennell DA, Popat S, Rintoul RC, Waller D, Ali C, Bille A, Fuller L, Ionescu A, Keni M, Kirk A, Koh P, Lau K, Mansy T, Maskell NA, Milton R, Muthukumar D, Pope T, Roy A, Shah R, Shamash J, Tasigiannopoulos Z, Taylor P, Treece S, Ashton K, Harris R, Joyce K, Warnes B, Mills N, Stokes EA, Rogers C; MARS 2 Trialists. Lim E, et al. BMJ Open. 2020 Sep 1;10(9):e038892. doi: 10.1136/bmjopen-2020-038892. BMJ Open. 2020. PMID: 32873681 Free PMC article.
METHODS AND ANALYSIS: The MARS 2 study is a UK multicentre open parallel group randomised controlled trial comparing the effectiveness and cost-effectiveness of surgery-(extended) pleurectomy decortication-versus no surgery for the treatment of pleural mesothelioma. …
METHODS AND ANALYSIS: The MARS 2 study is a UK multicentre open parallel group randomised controlled trial comparing the effec …
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators. Fennell DA, et al. Lancet Oncol. 2021 Nov;22(11):1530-1540. doi: 10.1016/S1470-2045(21)00471-X. Epub 2021 Oct 14. Lancet Oncol. 2021. PMID: 34656227 Free PMC article. Clinical Trial.
The randomisation sequence was generated within an interactive web response system (Alea); patients were stratified according to epithelioid versus non-epithelioid histology and were assigned in random block sizes of 3 and 6. ...This trial is registered with …
The randomisation sequence was generated within an interactive web response system (Alea); patients were stratified according to epit …
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Morabito A, Cecere FL, Ceresoli GL, Dawe DE, Zucali PA, Pagano M, Goffin JR, Sanchez ML, Gridelli C, Zalcman G, Quantin X, Westeel V, Gargiulo P, Delfanti S, Tu D, Lee CW, Leighl N, Sederias J, Brown-Walker P, Luo Y, Lantuejoul S, Tsao MS, Scherpereel A, Bradbury P, Laurie SA, Seymour L. Chu Q, et al. Lancet. 2023 Dec 16;402(10419):2295-2306. doi: 10.1016/S0140-6736(23)01613-6. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931632 Clinical Trial.
We hypothesised that the addition of pembrolizumab to platinum-pemetrexed would improve overall survival in patients with pleural mesothelioma. METHODS: We did this open-label, international, randomised phase 3 trial at 51 hospitals in Canada, Italy, and France. ... …
We hypothesised that the addition of pembrolizumab to platinum-pemetrexed would improve overall survival in patients with pleural mesothelio …
1,046 results